Efficacy and safety of tadalafil taken as needed for the treatment of erectile dysfunction in Asian men: Results of an integrated analysis

Asian Journal of Andrology

Volumn 11, Issue 4, 2009, Pages 423-433

  Guo, Ying Lu ^a   Viswanathan, Vijay P ^b   Chiang, Han Sun ^c   Choi, Hyung Ki ^d   Yip, Andrew Wai Chun ^e   Shen, Wei ^f   Kopernicky, Vladimir ^f  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b MV Hospital for Diabetes   (India)

^c FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^d Yonsei University College of Medicine   (South Korea)

^e KWONG WAH HOSPITAL   (Hong Kong)

^f Lilly USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TADALAFIL;

ADULT; AGED; ARTICLE; ASIAN; BACKACHE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEMOGRAPHY; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ERECTILE DYSFUNCTION; FLUSHING; GASTRITIS; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MYALGIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NOSE CONGESTION; PENIS ERECTION; RANDOMIZED CONTROLLED TRIAL; SEXUAL INTERCOURSE; SIDE EFFECT; SMOKING; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ASIA; CARBOLINES; DOUBLE-BLIND METHOD; ERECTILE DYSFUNCTION; HUMANS; MALE; MIDDLE AGED; PHOSPHODIESTERASE INHIBITORS; PLACEBOS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 69749083503     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1038/aja.2009.11     Document Type: Article

References (36)

1. Ayta IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int 1999; 84: 50-6.
2. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study. J Urol 1994; 151: 54-61.
3. Billups KL. Erectile dysfunction as an early sign of cardiovascular disease. Int J Impot Res 2005; 17(Suppl 1): S19-24.
4. Maas R, Schwedhelm E, Albsmeier J, Boger RH. The pathophysiology of erectile dysfunction related to endothelial dysfunction and mediators of vascular function. Vasc Med 2002; 7: 213-25.
5. Greenstein A, Chen J, Miller H, Matzkin H, Villa Y, et al. Does severity of ischemic coronary disease correlate with erectile function? Int J Impot Res 1997; 9: 123-6.
6. Fonseca V, Seftel A, Denne J, Fredlund P. Impact of diabetes mellitus on the severity of erectile dysfunction and response to treatment: Analysis of data from tadalafil clinical trials. Diabetologia 2004; 47: 1914-23.
7. Price DE, Gingell JC, Gepi-Attee S, Wareham K, Yates P, et al. Sildenafil: Study of a novel oral treatment for erectile dysfunction in diabetic men. Diabet Med 1998; 15: 821-5.
8. Ziegler D, Merfort F, van Ahlen H, Yassin A, Reblin T, et al. Efficacy and safety of flexible-dose vardenafil in men with type 1 diabetes and erectile dysfunction. J Sex Med 2006; 3: 883-91.
9. Brock GB, McMahon CG, Chen KK, Costigan T, Shen W, et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol 2002; 168: 1332-6.
10. Carson CC, Rajfer J, Eardley I, Carrier S, Denne JS, et al. The efficacy and safety of tadalafil: An update. BJU Int 2004; 93: 1276-81.
11. Lewis RW, Sadovsky R, Eardley I, O'Leary M, Seftel A, et al. The efficacy of tadalafil in clinical populations. J Sex Med 2005; 2: 517-31.
12. Morgentaler A, Barada J, Niederberger C, Donatucci C, Garcia CS, et al. Efficacy and safety of tadalafil across ethnic groups and various risk factors in men with erectile dysfunction: Use of a novel noninferiority study design. J Sex Med 2006; 3: 492-503.
13. Chen K-K, Jiann BP, Lin JS, Lee S-S, Huang S-T, et al. Efficacy and safety of on-demand oral tadalafil in the treatment of men with erectile dysfunction in Taiwan: A randomized, double-blind, parallel, placebo-controlled clinical study. J Sex Med 2004; 1: 201-8.
14. Choi HK, Ahn TY, Kim JJ, Kim SC, Paick JS, et al. A double-blind, randomised- placebo, controlled, parallel group, multicentre, flexible-dose escalation study to assess the efficacy and safety of sildenafil administered as required to male outpatients with erectile dysfunction in Korea. Int J Impot Res 2003; 15: 80-6.
15. Guo YL, Zhu JC, Pan TM, Ding Q, Wang YX, et al. Efficacy and safety of on-demand tadalafil for the treatment of erectile dysfunction in South-East Asian men. Int J Urol 2006; 13: 721-7.
16. Yip WC, Chiang HS, Mendoza JB, Tan HM, Li MK, et al. Efficacy and safety of on demand tadalafil in the treatment of East and Southeast Asian men with erectile dysfunction: A randomized double-blind, parallel, placebo-controlled clinical study. Asian J Androl 2006; 8: 685-92.
17. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, et al. The international index of erectile function (IIEF): A multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822-30.
18. Cappelleri JC, Siegel RL, Osterloh IH, Rosen RC. Relationship between patient self-assessment of erectile function and the erectile function domain of the international index of erectile function. Urology 2000; 56: 477-81.
19. Dunnett CW. A multiple comparison procedure for comparing several treatments with a control. J Am Stat Assoc 1955; 50: 1096-121.
20. Lim PH, Li MK, Ng FC, Chia SJ, Consigliere D, et al. Clinical efficacy and safety of sildenafil citrate (Viagra) in a multi-racial population in Singapore: A retrospective study of 1520 patients. Int J Urol 2002; 9: 308-15.
21. Tan HM, Moh CL, Mendoza JB, Gana T, Albano GJ, et al. Asian sildenafil efficacy and safety study (ASSESS-1): A double-blind, placebo-controlled, flexible-dose study of oral sildenafil in Malaysian, Singaporean, and Filipino men with erectile dysfunction. The Assess-1 Study Group. Urology 2000; 56: 635-40.
22. Carrier S, Brock GB, Pommerville PJ, Shin J, Anglin G, et al. Efficacy and safety of oral tadalafil in the treatment of men in Canada with erectile dysfunction: A randomized, double-blind, parallel, placebo-controlled clinical trial. J Sex Med 2005; 2: 685-98.
23. Eardley I, Gentile V, Austoni E, Hackett G, Lembo D, et al. Efficacy and safety of tadalafil in a Western European population of men with erectile dysfunction. BJU Int 2004; 94: 871-7.
24. Seftel AD, Wilson SK, Knapp PM, Shin J, Wang WC, et al. The efficacy and safety of tadalafil in United States and Puerto Rican men with erectile dysfunction. J Urol 2004; 172: 652-7.
25. Nagao K, Kimoto Y, Marumo K, Tsujimura A, Vail GM, et al. Efficacy and safety of tadalafil 5, 10, and 20 mg in Japanese men with erectile dysfunction: Results of a multicenter, randomized, double-blind, placebo-controlled study. Urology 2006; 68: 845-51.
26. Marumo K, Imaoka T, Fujimoto K, Watts S, Stothard D, et al. A comparison of the efficacy and tolerability of tadalafil 10 mg and 20 mg in Japanese patients with severe erectile dysfunction. J Sex Med 2007; 4: 745-52.
27. De Tejada IS, Emmick J, Anglin G, Fredlund P, Pullman W. The effect of as-needed IC351 treatment of erectile dysfunction in men with diabetes. Diabetologia 2001; 44(Suppl 1): A295.
28. Carson CC, Burnett AL, Levine LA, Nehra A. The efficacy of sildenafil citrate (Viagra) in clinical populations: An update. Urology 2002; 60 (Suppl 2): 12-27.
29. Montorsi F, Verheyden B, Meuleman E, Junemann KP, Moncada I, et al. Long-term safety and tolerability of tadalafil in the treatment of erectile dysfunction. Eur Urol 2004; 45: 339-44.
30. Joelson S, Joelson IB, Wallander MA. Geographical variation in adverse event reporting rates in clinical trials. Pharmacoepidemiol Drug Saf 1997; 6 (Suppl 3): S31-5.
31. Forgue ST, Patterson BE, Bedding AW, Payne CD, Phillips DL, et al. Tadalafil pharmacokinetics in healthy subjects. Br J Clin Pharmacol 2006; 61: 280-8.
32. Yamaguchi T, Uenaka K, Imaoka T. Pharmacological, pharmacokinetic, and clinical profile of tadalafil (Cialis). Nippon Yakurigaku Zasshi 2008; 131: 469-77.
33. Corona G, Razzoli E, Forti G, Maggi M. The use of phosphodiesterase 5 inhibitors with concomitant medications. J Endocrinol Invest 2008; 31: 799-808.
34. Hatzichristou D, Moysidis K, Apostolidis A, Bekos A, Tzortzis V, et al. Sildenafil failures may be due to inadequate patient instructions and follow-up: A study on 100 nonresponders. Eur Urol 2005; 47:518-22.
35. Ahn TY, Lee SW, Kim SW, Yang DY, Park NC, et al. Treatment preferences in men with erectile dysfunction: An open label study in Korean men switching from sildenafil citrate to tadalafil. Asian J Androl 2007; 9: 760-70.
36. Yaman O, Chlosta P, Kovalev V, Shenfeld O, Pacik D, et al. Switching from sildenafil (viagra) to tadalafil (cialis) in men with erectile dysfunction in Central/Eastern Europe and Eastern Mediterranean regions: Assessment of sexual attempt behavior and psychological and interpersonal relationship scales. J Sex Med 2005; 2 (Suppl 1): 65.